The specialty pharmaceutical company Medios DE000A1MMCC8 benefited at the start of the year from good business with patient-specific therapies and an acquisition.

With revenue increasing by just over six percent to just under €485 million, adjusted earnings before interest, taxes, depreciation, and amortization (adjusted EBITDA) increased by 53 percent year-on-year to €23.1 million, the SDAX-listed company announced in Berlin on Tuesday. The corresponding margin increased by 1.5 percentage points to 4.8 percent. The bottom line also improved significantly, to €6.4 million, compared to €4 million a year earlier.

Outgoing Medios CEO Matthias Gärtner expressed his satisfaction with the start to the year. Thanks to positive momentum from all operating divisions and the strategic focus on higher-margin products, "we have already achieved our target margin for the full year in the first quarter and are continuing our sustained growth path." The manager accordingly reaffirmed his targets for the full year 2025, which call for an increase in sales to around €2 billion and an increase in operating profit by a good fifth to around €96 million.